Targeting PCSK9, through an innovative cVLP-based vaccine, enhanced the therapeutic activity of a cVLP-HER2 vaccine in a preclinical model of HER2-positive mammary carcinoma

Targeting PCSK9, through an innovative cVLP-based vaccine, enhanced the therapeutic activity of a cVLP-HER2 vaccine in a preclinical model of HER2-positive mammary carcinoma

Abstract Background HER2-targeted therapies have revolutionized the treatment of HER2-positive breast cancer patients, leading to significant improvements in tumor response rates and survival. However, resistance and incomplete response remain considerable challenges. Proprotein convertase subtilisi...

Full description

Saved in:
Bibliographic Details
Main Authors: Laura Scalambra, Francesca Ruzzi, Olga Maria Pittino, Maria Sofia Semprini, Chiara Cappello, Stefania Angelicola, Arianna Palladini, Patrizia Nanni, Louise Goksøyr, Cyrielle Fougeroux, Manuel L. Penichet, Adam Frederik Sander, Pier-Luigi Lollini
Format: Article
Language:English
Published: BMC 2025-01-01
Series:Journal of Translational Medicine
Subjects:
Breast cancer
HER2
Therapy resistance
Cancer progression
PCSK9
Therapeutic cancer vaccines
Online Access:https://doi.org/10.1186/s12967-025-06126-w
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s12967-025-06126-w

Similar Items